Diagnostics and correction of oxidative status of patients with schizophrenia
Abstract
Oxidative stress is a significant participant in the pathophysiology of multiple brain disorders, including schizophrenia. Here we highlight roles for oxidative stress as a common mechanism by which varied genetic and epidemiologic risk factors impact upon functional and structure impairment in brain that underlie the schizophrenia syndrome. Oxidative injury in schizophrenia may be caused not only by pathophysiological processes but partly by treatment with antipsychotics. Many studies have been conducted in order to probe the potential protective effects of typical and atypical antipsychotic drugs on the oxidant-anti-oxidant system and lipid peroxidation. Also it is to be discussed if antioxidants should have a place in the treatment of patients with schizophrenia.
About the Authors
M. V. Ivanov
St. Petersburg Research Institute of Psychoneurology n.a. V. M. Bekhterev
Russian Federation
Russian Federation
L. V. Shchedrina
St. Petersburg Research Institute of Psychoneurology n.a. V. M. Bekhterev
Russian Federation
Russian Federation
Yu. I. Tarkhova
St. Petersburg Psychiatric Hospital No.1 n.a. P. P. Kashchenko
Russian Federation
Russian Federation
N. D. Eshchenko
Saint Petersburg State University
Russian Federation
Russian Federation
S. G. Dagayev
Institute of Toxicology
Russian Federation
Russian Federation
References
1. Болевич C. Б., Малыгин В.Л., Силина Е. В., Орлов В. А. Свободнорадикальные процессы и их коррекция при шизофрении // Психиатрия и психофармакотерапия им. П. Б. Ганнушкина.- 2013.- Т. 3.- С. 33-38.
2. Дубинина Е.Е. Продукты метаболизма кислорода в функциональной активности клеток. Спб: Издательство Медицинская пресса, 2006. С: 113-135.
3. Иванов М. В., Дубинина Е. Е., Незнанов Н. Г., Михайлова В. А. Окислительный стресс в психиатрии и неврологии. СПб.: ФГБУ «Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева».-2016.-С. 59-75.
4. Насырова Р. Ф., Иванов М. В., Незна-нов Н. Г. Введение в психофармакогенетику.- Спб: Издательский центр Спб НИПНИ им. В. М. Бехтерева. - 2015.- С. 95-97.
5. Шаповалов Д. Л. Применение мексидо-ла и его комбинации с декстраном 40 для коррекции негативных симптомов и нейрокогнитивного дефицита у пациентов с параноидной шизофренией. Мексидол в клинике и эксперименте (по материалам II Научно-практической олимпиады). Приложение 1 к журналу «Бюллетень экспериментальной биологии и медицины» за 2012 год. М.: Издательство РАМН, 2012.
6. Boskovic M., Vovk T., Kores Plesnicar B., Grabnar I. Oxidative Stress in Schizophrenia. // Curr Neuropharmacol.-2011.-Vol. 9 (2).- P. 301-312.
7. Demirci K, Ôzçankaya R, Yilmaz HR, Yigit A, Uguz AC, Karakus K, Demirdaç A, Akpinar A. Paliperidone regulates intracellular redox system in rat brain: Role of purine mechanism // Redox Rep. - 2015.- Vol. 20(4). - P. 170-6.
8. Dietrich-Muszalska A., Kontek B., Rabe-Jabtonska J. Quetiapine, Olanzapine and Haloperidol Affect Human Plasma Lipid Peroxidation in vitro // Neuropsychobiology.- 2011.- Vol. 63.- P. 197-201.
9. Fregonesi Brinholi F., Coneglian de Farias C., Landucci Bonifacio K., Higachi L., Casa-grande R., Gastaldello Moreira E., Sabbatini Barbosa D. Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models // Biomedicine & Pharmacotherapy.- 2016.- Vol. 81.- P. 411-415.
10. Koga M., et al., Implicationsfor reactiveoxygen species in schizophrenia pathogenesis // Schizophr. Res.- 2015.- Vol. 176 (1).- P. 52-71.
11. Kriisa K., Haring L., Vasar E., Koido K., Janno S., Vasar V., Zilmer K., Zilmer M. Antipsychotic Treatment Reduces Indices of Oxidative Stress in First-Episode Psychosis Patients // Oxidative Medicine and Cellular Longevity. Volume 2016 (2016), Article ID 9616593.- P. 1-7.
12. Magalhâes P. V., Dean O., Andreazza A. C., Berk M., Kapczinski F. Antioxidant treatments for schizophrenia // The Cochrane Library.-2011.- I. 1.- P. 1-10.
13. Noto C., Ota V., Gadelha A., Noto M., Barbosa D., Bonifacio K., Nunes S., Cordeiro Q., Belangero S., Bressan R., Maes M., Brietzke E. Oxidative stress in drug naive first episode psychosis and antioxidant effects of risperidone // J Psychiatr Res.-2015.- Vol. 68. - P. 210-6.
14. Raffa M., Atig F., Mhalla A., Kerkeni A., Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients // BMC Psychiatry. - 2011.- Vol. 11.- P. 124.
15. Reyazuddin M., Azmi S. A., Islam N., Rizvi A. Oxidative stress and level of ant'ioxidant enzymes in drug-naive schizophrenics // Indian J Psychiatry.- 2014.- Vol. 56 (4). - P. 344-349.
16. Sadowska-Bartosz I., Galiniak S., Bartosz G., Zuberek M., Grzelak A., Dietrich-Muszalska A. Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia // Schizophrenia Res.- 2016.- Vol. 176.- Issues2-3.- P. 245-251.
17. Zhang X., Chen D., Tan Y., Tan S., Wang Z., Yang F., Okusaga O., Zunta-Soares G., Soares J. The interplay between BDNF and oxidative stress in chronic schizophrenia. // Psychoneuroendocrinology.- 2015.- Vol. 51.- P. 201-8.
18. Zhang X., Zhou D., Shen Y., Zhang P., Zhang W., Liang J., Chen D., Xiu M., Kosten T., Kosten T. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia // Neuropharmacology. - 2012.- Vol. 62 (5-6).- P. 1928-34.
Review
For citations:
Ivanov M.V., Shchedrina L.V., Tarkhova Yu.I., Eshchenko N.D., Dagayev S.G. Diagnostics and correction of oxidative status of patients with schizophrenia. Medical alphabet. 2018;1(1):50-56. (In Russ.)
Views:
323
Email this article 